Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate.
about
The roles of hyaluronan/RHAMM/CD44 and their respective interactions along the insidious pathways of fibrosarcoma progressionEfficacy and toxicity of peritumoral delivery of nanoconjugated cisplatin in an in vivo murine model of head and neck squamous cell carcinoma.Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head & neck.Doxorubicin-loaded silk films: drug-silk interactions and in vivo performance in human orthotopic breast cancer.Synthesis and characterization of a multi-arm poly(acrylic acid) star polymer for application in sustained delivery of cisplatin and a nitric oxide prodrug.Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer.Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer.Lymphatic trafficking kinetics and near-infrared imaging using star polymer architectures with controlled anionic characterPharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents.Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapiesIntraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer.In vivo efficacy of nano hyaluronan-conjugated cisplatin for treatment of murine melanoma.Advances in lymphatic imaging and drug delivery.Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugatesPrevention of nodal metastases in breast cancer following the lymphatic migration of paclitaxel-loaded expansile nanoparticles.Hyaluronan as a therapeutic target in human diseasesMulti-arm polymeric nanocarrier as a nitric oxide delivery platform for chemotherapy of head and neck squamous cell carcinoma.Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells.Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatmentHyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines.Advanced drug delivery to the lymphatic system: lipid-based nanoformulations.Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomasImpact of molecular weight on lymphatic drainage of a biopolymer-based imaging agentA novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo.Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo.Therapeutic applications of hyaluronan.Targeting and delivery of platinum-based anticancer drugs.Lymphatic system: a prospective area for advanced targeting of particulate drug carriers.Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.Hyaluronic acid conjugates as vectors for the active targeting of drugs, genes and nanocomposites in cancer treatment.Self-microemulsifying drug delivery system (SMEDDS)--challenges and road ahead.Development and Validation of an Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Method for Quantitative Analysis of Platinum in Plasma, Urine, and Tissues.Nanoparticle formulations of cisplatin for cancer therapy.Co-delivery of siRNA and hypericin into cancer cells by hyaluronic acid modified PLGA-PEI nanoparticles.Enhanced transdermal lymphatic drug delivery of hyaluronic acid modified transfersomes for tumor metastasis therapy.A silica-calcium-phosphate nanocomposite drug delivery system for the treatment of hepatocellular carcinoma: in vivo study.Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer.Phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate in dogs with naturally occurring malignant tumors.Preparation, characterisation and preliminary antitumour activity evaluation of a novel nanoparticulate system based on a cisplatin-hyaluronate complex and N-trimethyl chitosan.Positive hyaluronan/PEI/DNA complexes as a target-specific intracellular delivery to malignant breast cancer.
P2860
Q27025313-5B96DBAF-B0CB-49BD-B58B-02C1BBFD1E88Q30420306-A19CBF97-4491-4F43-99C5-106DEF6C4CB5Q30474692-7B792877-2D2E-4994-8FBC-47D9BFA79636Q30525060-D0EE7F2B-D45B-45FF-8B75-8B0CDC648587Q31019887-11416DCF-2D75-473F-8BFF-FB825B560C8EQ33862921-99EFC5E6-A2BE-4B99-A4EA-F2DA5ED6A7A3Q34054263-21699C06-61F2-4FB1-A2D5-39DAB6EFECDEQ34995612-8736366B-2D7F-47FD-B6BD-007BC3C26C8AQ35009186-5B9351FD-25B9-41D3-8747-4D23277628CBQ35009191-0E2F1331-61D8-4094-8825-AC0A351A770EQ35032664-A38B31BF-97F9-48E4-966A-5499D49448A5Q35130444-7F6C7671-6BA6-457A-8A73-E391A7E09BC4Q35188498-C31D2302-2743-4A67-AC59-AB14BCF88112Q36204729-61A0E293-19AD-435C-86F1-C28AD062F928Q36521096-89FEBAD5-DCE6-4445-822C-607D08B58751Q36578627-9BD040F6-0349-4ACA-B518-60C6A67C9174Q36609101-EB84E895-AA9B-47EB-8A3A-33578852B638Q36828500-61022546-9371-4A93-B990-334B2052D17EQ36893273-AD26138E-FCFF-4818-92FE-8B885E076E8AQ36948510-D2BEDE70-610C-4D7D-876F-0E3B55F414DDQ37066550-9AD8A8B0-8075-4868-A4C3-B012BC80E753Q37186800-33CA2787-4894-432C-93F8-F55EC9421734Q37327825-EB64D095-7715-42E7-9352-429469E5469AQ37470083-C3F704F5-0165-4460-B294-6C8953CDC7DDQ37543923-AE7937BD-D19D-42D7-BF91-0EA050870C9EQ37696315-6089CF89-67B6-44CA-B749-FA7AD2C66003Q38050063-388B6169-59DF-48D5-8409-47416E18CCD3Q38172276-9FDB3779-210D-4D0A-BD7C-B95FBDE299A6Q38183786-A30DDBD0-66E1-4B57-91F4-1B427EAC1795Q38197045-8137CCE0-1A26-4A64-8649-0F212EA72930Q38199539-CD13022C-699C-4253-BFAE-E7B7D8F25146Q38436491-9D3C4829-9392-47BF-AD17-3AB0EE370E79Q38723829-FBE0E994-CE1B-4206-B557-8C1B911604A4Q38827570-870DD2ED-17F6-4764-ABB5-56F8417CE17DQ38930219-EDC8E633-BA46-4768-9878-79AE6E7A4763Q39115629-34208587-34EB-42EA-AA14-0B6183706FA1Q39120205-40E6A437-8384-40B1-9A52-F26AD157095EQ39436032-B0279E8C-B0ED-4430-8215-1603688F5BA3Q39758165-5C4E569F-72B0-4DA0-816B-AD0AB918B5BCQ39834920-9E07997F-B6E5-4AC8-A460-CB624D855AFA
P2860
Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate.
@ast
Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate.
@en
type
label
Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate.
@ast
Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate.
@en
prefLabel
Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate.
@ast
Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate.
@en
P2093
P2860
P1476
Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate
@en
P2093
Mark S Cohen
Shuang Cai
Taryn R Bagby
P2860
P304
P356
10.1016/J.JSS.2008.02.048
P577
2008-03-26T00:00:00Z